Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in… EP News Bureau Nov 22, 2024 HS-20093: A breakthrough ADC poised to redefine second-line SCLC care in China, strengthening Jiangsu Hansoh's oncology leadership…
Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData EP News Bureau Nov 20, 2023 GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China
